Business Context and Reporting Period
This Form 8-K Current Report was filed by Lifemd, Inc. on December 11, 2023 (dated December 13, 2023). The filing primarily discloses a strategic collaboration and a concurrent private placement of equity securities with Medifast, Inc., as well as updates on prior acquisition payments and employee equity issuances.
Key Financial Metrics and Transactions
- Private Placement Proceeds: The Company issued 1,224,425 shares of common stock to Jason Pharmaceuticals, Inc. (a Medifast subsidiary) at $8.1671 per share, raising approximately $10 million.
- Collaboration Funding: Medifast agreed to pay a total of $10 million to support the collaboration.
- $5 million paid at closing (December 12, 2023).
- $2.5 million due March 31, 2024.
- $2.5 million due June 30, 2024 (or earlier upon milestone achievement).
- Acquisition Payment: The Company issued 117,583 shares of common stock on October 17, 2023, as the fourth installment payment under the Cleared Technologies acquisition agreement. The total purchase price for Cleared was reduced to $3.67 million.
- Employee Equity Issuances (Q4 2023 to date):
- 526,125 shares issued for vested RSUs and RSAs.
- 37,500 shares issued upon exercise of stock options.
Note: This filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the reporting period.
Material Changes and Governance
The most significant material change is the entry into a collaboration agreement with Medifast, Inc., which includes funding for platform enhancements and operational support. Additionally, the Company granted the Purchaser (Jason Pharmaceuticals, Inc.) the right to appoint one non-voting observer to the Board of Directors for the duration of the collaboration.
Outlook, Risks, and Unusual Items
- Future Cash Inflows: The Company expects to receive $5 million in two installments in 2024, contingent on the collaboration timeline or specific program milestones.
- Registration Rights: A Registration Rights Agreement was executed, requiring the Company to register the shares sold to Medifast upon demand.
- Regulatory Status: All equity issuances described were made in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D.
Investor Verification Checklist
- Verify the specific terms and milestones required to accelerate the remaining $5 million collaboration payments.
- Review the impact of the 1,224,425 new shares on existing shareholder dilution.
- Confirm the status of the final installment payment for the Cleared Technologies acquisition due January 15, 2024.
- Monitor the appointment of the Medifast board observer and any potential influence on corporate governance.